Royce & Associates LP Grows Stock Holdings in SiBone $SIBN

Royce & Associates LP raised its position in shares of SiBone (NASDAQ:SIBN) by 82.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 296,067 shares of the company’s stock after purchasing an additional 134,016 shares during the period. Royce & Associates LP owned approximately 0.68% of SiBone worth $5,838,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd purchased a new stake in SiBone during the fourth quarter valued at about $29,000. State of Wyoming purchased a new stake in SiBone during the second quarter valued at about $55,000. Canada Pension Plan Investment Board purchased a new stake in SiBone during the second quarter valued at about $68,000. Larson Financial Group LLC increased its holdings in shares of SiBone by 42.3% in the fourth quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock worth $70,000 after buying an additional 1,061 shares during the period. Finally, Quarry LP increased its holdings in shares of SiBone by 862.6% in the third quarter. Quarry LP now owns 4,861 shares of the company’s stock worth $72,000 after buying an additional 4,356 shares during the period. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Insiders Place Their Bets

In related news, Director Mika Nishimura sold 4,100 shares of the business’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $13.83, for a total transaction of $56,703.00. Following the transaction, the director owned 32,716 shares in the company, valued at $452,462.28. The trade was a 11.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Laura Francis sold 14,957 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $14.71, for a total value of $220,017.47. Following the transaction, the chief executive officer owned 503,444 shares in the company, valued at approximately $7,405,661.24. This represents a 2.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 29,572 shares of company stock worth $418,831 in the last quarter. 4.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Wall Street Zen downgraded SiBone from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Truist Financial reiterated a “buy” rating and issued a $18.00 price objective (down from $20.00) on shares of SiBone in a report on Tuesday, May 12th. Finally, TD Cowen decreased their price objective on SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, SiBone presently has an average rating of “Moderate Buy” and a consensus target price of $23.00.

SiBone Stock Down 2.2%

Shares of NASDAQ:SIBN opened at $14.10 on Friday. SiBone has a 1 year low of $11.48 and a 1 year high of $21.89. The company has a market cap of $625.32 million, a PE ratio of -36.15 and a beta of 0.67. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.99 and a quick ratio of 8.34. The stock’s 50-day moving average is $13.53 and its 200 day moving average is $16.05.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%.The company had revenue of $52.59 million for the quarter, compared to the consensus estimate of $51.16 million. Sell-side analysts anticipate that SiBone will post -0.44 EPS for the current year.

SiBone Company Profile

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.